Results 151 to 160 of about 2,154,176 (393)

Specificity and mechanism of action of some commonly used protein kinase inhibitors.

Biochemical Journal, 2000
S. Davies, Helen Reddy, M. Caivano, P. Cohen   +3 more
semanticscholar   +2 more sources

Two well‐defined motifs in the cAMP‐dependent protein kinase inhibitor (PKIα) correlate with inhibitory and nuclear export function [PDF]

, 1999
Jennifer A. Hauer, Philippe Barthe, Susan S. Taylor, Joseph Parello, André Padilla   +4 more
openalex   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Additional file 3 of Quantitative Structure–Mutation–Activity Relationship Tests (QSMART) model for protein kinase inhibitor response prediction

, 2020
Liang‐Chin Huang, Wayland Yeung, Ye Wang, Huimin Cheng, Aarya Venkat, Sheng Li, Ping Ma, Khaled Rasheed, Natarajan Kannan   +8 more
openalex   +1 more source

The selectivity of protein kinase inhibitors: a further update.

Biochemical Journal, 2007
J. Bain, Lorna Plater, M. Elliott, N. Shpiro, J. Hastie, Hilary, Mclauchlan, Iva Klevernic, Simon Arthur, D. Alessi, P. Cohen   +10 more
semanticscholar   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Systematic Analysis of Covalent and Allosteric Protein Kinase Inhibitors. [PDF]

Molecules, 2023
Xerxa E, Laufkötter O, Bajorath J.
europepmc   +1 more source

Synergistic Interactions of 5-Fluorouracil with Inhibitors of Protein Kinase CK2 Correlate with p38 MAPK Activation and FAK Inhibition in the Triple-Negative Breast Cancer Cell Line [PDF]

, 2020
Patrycja Wińska, Olena Karatsai, Monika Staniszewska, Mirosława Koronkiewicz, Konrad Chojnacki, Maria Jolanta Rędowicz   +5 more
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Supplementary Table 1 from Inhibition of <i>S</i>-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma

, 2023
Dana‐Lynn T. Koomoa, Tamás Borsics, David J. Feith, Craig C. Coleman, Christopher J. Wallick, Ivonne Gamper, Anthony E. Pegg, André S. Bachmann   +7 more
openalex   +1 more source